Brian McKelligon - 14 Mar 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President/CEO, Director
Signature
/s/ Brian McKelligon
Issuer symbol
AKYA
Transactions as of
14 Mar 2023
Net transactions value
-$44,337
Form type
4
Filing time
16 Mar 2023, 16:20:16 UTC
Previous filing
27 Feb 2023
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $1,515 +5,000 +3.1% $0.3030* 165,000 14 Mar 2023 Direct
transaction AKYA Common Stock Sale $43,610 -4,774 -2.9% $9.14 160,226 14 Mar 2023 Direct F1, F2
transaction AKYA Common Stock Sale $2,241 -226 -0.14% $9.92 160,000 14 Mar 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.5% $0.000000 333,129 14 Mar 2023 Common Stock 5,000 $0.3030 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated May 16, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.77 to $9.765, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.885 to $10.10, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment.